XML 81 R53.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue - Additional Information (Detail) € in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2024 EUR (€) | Jan. 31, 2024 EUR (€) | Nov. 30, 2023 USD ($) | Nov. 30, 2018 | Dec. 31, 2024 EUR (€) CommercialCustomer | Dec. 31, 2024 USD ($) CommercialCustomer | Dec. 31, 2023 EUR (€) CommercialCustomer | Dec. 31, 2022 EUR (€)
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Revenue |  |  |  |  | € 363,641 |  | € 266,718 | € 51,174
Number of commercial customers | CommercialCustomer |  |  |  |  | 4 | 4 | 4 |
Adjustment to Prior Periods Estimates and Assumptions [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Revenue |  |  |  |  | € 4,700 |  |  |
VISEN Pharmaceuticals [member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Proportion of ownership interest in associate |  |  |  | 50.00% | 43.90% | 43.90% |  |
Novo Nordisk [member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Upfront development and regulatory milestones potentially to be received | € 285,000 |  |  |  |  |  |  |
Upfront fee for exclusive license | 100,000 |  |  |  |  |  |  |
Maximum additional development and regulatory milestones potentially to be received | € 77,500 |  |  |  |  |  |  |
Third Party Investors [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Commitment from investors |  | € 150,000 |  |  |  |  |  |
Teijin [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Upfront payment received | $ |  |  | $ 70,000,000 |  |  |  |  |
Maximum additional development and regulatory milestones potentially to be received | $ |  |  | $ 175,000,000 |  |  |  |  |
Royalties and Milestones [Member] | Third Party Investors [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Recognized as revenue | $ |  |  |  |  |  | $ 0 |  |
Royalties and Milestones [Member] | Teijin [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Recognized as revenue |  |  |  |  | € 0 |  |  |
Licenses [Member] | Novo Nordisk [member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | 95,300 |  |  |
Licenses [Member] | Third Party Investors [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | 27,100 |  |  |
Licenses [Member] | Teijin [Member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | € 63,700 |
Commercial customers [member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Revenue |  |  |  |  | € 225,728 |  | € 178,663 | € 35,659
Commercial customers [member] | Bottom of range [member] |  |  |  |  |  |  |  |
Disclosure of performance obligations [line items] |  |  |  |  |  |  |  |
Perentage of sale to commercial customers |  |  |  |  | 10.00% | 10.00% | 10.00% |

X
- Definition Capital commitment from investors. + References No definition available. + Details
Name: | asnd_CapitalCommitmentFromInvestors
Namespace Prefix: | asnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum additional development and regulatory milestones potentially to be received. + References No definition available. + Details
Name: | asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
Namespace Prefix: | asnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of commercial customers. + References No definition available. + Details
Name: | asnd_NumberOfCommercialCustomers
Namespace Prefix: | asnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront development and regulatory milestones potentially to be received. + References No definition available. + Details
Name: | asnd_UpfrontDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
Namespace Prefix: | asnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee for exclusive license. + References No definition available. + Details
Name: | asnd_UpfrontFeeForExclusiveLicense
Namespace Prefix: | asnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | asnd_UpfrontPaymentReceived
Namespace Prefix: | asnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfPerformanceObligationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of the entity's revenue. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_PercentageOfEntitysRevenue
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 28 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 23 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 32 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 33 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard -URIDate 2024-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard -URIDate 2024-03-27 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2024-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2024-03-27 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 82 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard -URIDate 2024-03-27 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard -URIDate 2024-03-27 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2024-01-01 -Paragraph 113 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=asnd_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=asnd_TeijinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=asnd_LicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |